NEUROTOXICOLOGICAL TESTING OF CLINICAL CANDIDATE DRUGS

临床候选药物的神经毒理学测试

• 批准号: 2873560
• 负责人: GERALD J SCHAEFER
• 金额: --
• 依托单位: MPI RESEARCH, LLC
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-15 至 2000-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2873560
• 关键词: Rodentias; drug abuse chemotherapy; drug addiction antagonist; drug adverse effect; drug screening /evaluation; histology; neurotoxins

The mission of the Medications Development Division (MDD) of NIDA is to develop safe and efficacious medical treatments for cocaine and opiate abuse/dependence. These therapeutic agents need to have low abuse liability, diminish the reinforcing effects, curtail the rewarding effects, and decrease the addictive attributes of drugs of abuse. Moreover, there is also a need to moderate and/or eliminate the symptoms associated with withdrawal, and ultimately reduce the use and subsequent relapse to renewed use of these illicit drugs. NIDA intends to minimize the risk of injury to the nervous systems of patients undergoing treatment with new drugs developed by MDD. The primary objective of this research and development contract is to assess the potential of experimental new medical treatment compounds (test compounds) to induce neurotoxicity. Test compounds may interact with illicit drugs and/or a brain altered by such drugs in a manner that will damage the brain. In this contract , rodents will be exposed to test compounds and their brains examined under light microscopic techniques to reveal possible damage to brain tissue caused by the test compound or its interaction with cocaine, methamphetamine or other abused substances. Data generated by this contract will help to determine the safety of candidate medications and will guide decision- making concerning advancement of test compounds in the development process.

NIDA的药物开发部（MDD）的任务是 为可卡因开发安全有效的药物治疗 滥用/依赖。 这些治疗剂需要低滥用 责任，减少增强效果，减少奖励效果， 并减少滥用药物的上瘾属性。 而且， 还需要适度和/或消除症状 与撤离相关，并最终减少使用和 随后复发，重新使用了这些非法药物。 NIDA打算 为了最大程度地减少患者神经系统受伤的风险 接受MDD开发的新药治疗。 这项研究和发展合同的主要目标是 评估实验性新医疗化合物的潜力 （测试化合物）诱导神经毒性。 测试化合物可能相互作用 用非法药物和/或以某种方式改变此类药物的大脑 那会损害大脑。 在本合同中，啮齿动物将暴露 测试化合物及其在光显微镜下检查的大脑 揭示测试造成的脑组织可能损害的技术 化合物或与可卡因，甲基苯丙胺或其他的相互作用 滥用物质。 该合同产生的数据将有助于 确定候选药物的安全性，并将指导决策 - 关于开发中测试化合物的进步 过程。